Cardiac arrest after intrauter&e instillation of 32% dextran-70 during hysteroscopy
To the Editor: We describe a patient without known allergies who presented for hysteroscopy. Anaesthesia was induced with propofol and sufentanil. Shortly after uterine distension with 32% dextran-70, the patient experienced sudden, severe, sinus bradycardia and hypotension, progressing rapidly to asystole. Resuscitation with chest compression, atropine and epinephrine was begun. The clinical diagnosis of an anaphylactic reaction to dextran was made and methylprednisolone, diphenhydramine, and cimetidine were administered. The patient was successfully resuscitated and recovery was complete.
An allergy consultant established the diagnosis of anaphylaxis to dextran and recommended three days Of/v steroids and H, and H2 blockers. Serum tryptase concentration shortly after the event was 1.5 U-ml -j (normal <0.5 U" ml-J). This is a specific indicator of mast cell mediator release and is essentially absent from normal serum or from serum collected from patients suffering hypotension due to other causes, i It confirms anaphylaxis and mast cell degranulation was associated with the cardiovascular collapse.
Dextran is a polysaccharide molecule marketed in several formulations. Hysteroscopy is commonly performed using 32% dextran-70 as the distending media. Adverse reactions to dextran include volume overload, pulmonary oedema, coagulopathy, and dextran-indueed anaphylactoid/anaphylactic reaction (DIAR). The incidence of DIARs is reported to be as common as 1 in 383, 2 and can occur when as little as 0.5-1 ml of dextran enters the circulation. Previous exposure to dextran is not necessary for a DIAR to occur since antibodies may be formed by exposure to naturally occurring polysaccharides.
Dextran-1 (Promit) decreases the incidence of DIARs when administered prior to intravenous administration of higher molecular weight dextrans.3 It is safe, effective and has no known eontmindications. 4 Dextran-I is a monovalent hapten which binds to only one antibody. This blocks antibody binding by high molecular weight dextrans, preventing immune-complex formation. We recommend that clinicians consider administration of 15% dextran-1, 20 ml /v, two minutes before instillation of high molecular weight dextran solutions into the uterus for hysteroscopy. 3, 4 
